| Date | Title | Description |
| 10.02.2026 | Chugai and Araris Biotech AG Enter License Agreement for Araris' Linker-Payload ADC Technology AraLinQ® | TOKYO, JAPAN, February 10, 2026 /EINPresswire.com/ -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai") and Araris Biotech AG (hereafter "Araris") today announced that Chugai has exercised its option unde... |
| 24.01.2026 | Swiss VC Powerhouse Vi Partners Secures New Fund, Marks 25 Years of Innovation | Swiss venture capital titan Vi Partners celebrates 25 years of market leadership. It announced a significant first close for its new CHF 150 million (approximately €161M) fund. This strategic investment vehicle targets early-stage technolog... |
| 22.01.2026 | Vi Partners marks 25 years with first close of €161M new venture fund | Vi Partners this week announced the first close of its latest venture capital fund, targeting €161 million (CHF 150 million). It coincides with Vi Partners' 25th anniversary, marking a quarter-century of continuous venture capital activity.... |
| 21.01.2026 | Vi Partners: first closing of new CHF 150 million fund completed |
Since its founding in 2001, Vi Partners – Switzerland’s longest-standing Venture Capital firm - has supported successive generations of entrepreneurs and contributed to the development of Switzerland as a leading hub for technology and hea... |
| 04.07.2025 | Araris-Team sichert sich den mit 100‘000 Euro dotierten Strüngmann Award |
Das Gründerteam von Araris Biotech kann auf eine der erfolgreichsten Biotech-Firmengründungen der Schweiz in den vergangenen Jahren zurückblicken. Das 2019 aus dem Paul-Scherrer-Institut gegründete Spin-off hat eine proprietäre Linker-Payl... |
| 30.05.2025 | Schweizer Biotech-Startups dominieren europäischen Award |
Das Komitee des Strüngmann Awards hat diese Woche die diesjährigen Finalistinnen und Finalisten bekanntgegeben. Vergeben wird der mit 100.000 Euro dotierte Preis am 3. Juli. In das Finale geschafft haben es:
Dragan Grabulovski | Philipp Sp... |
| 28.03.2025 | Schroders upgrades Revolut stake in former Woodford trust by 85 per cent | A Schroders trust formerly run by star stockpicker Neil Woodford has upgraded the value of its stake in Revolut by 85 per cent, implying the fintech firm is worth $48bn (£37.1bn).
The Schroders valuation would put Revolut, which has been mu... |
| 17.03.2025 | Taiho Pharmaceutical to acquire Araris Biotech for up to USD 1.1 billion |
Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and pioneering the development of best-in-class ADCs with superior design, high linker solubility and simple manufacturing that address the shortcomings of current ... |
| 08.01.2025 | Araris enters multi-million contract with Chugai |
Araris Biotech is a leading independent company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ proprietary conjugation and multi-payload technology... |
| 26.09.2024 | Araris Biotech expands its IP portfolio |
Founded as spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, Araris Biotech has developed AraLinQ, a proprietary antibody-drug conjugate (ADC) technology that enables best-in-class ADCs with significantly enhanced eff... |
| 25.09.2024 | An unprecedented 66 alumni from Venture Kick clinched positions in the TOP 100 Swiss Startup Awards 2024 ranking, setting a new record | Venture Kick alumni were highlighted in the thirteenth edition of the TOP 100 Swiss Startup Awards annual ranking, with alums sweeping the podium, as well as 9 of the top 10 positions.
9 Venture Kick startups ranked in the TOP 10
#1 DePoly
... |
| 06.03.2024 | Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 | - |
| 12.11.2023 | Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical | AU ZH, SWITZERLAND, November 8, 2023 – Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris... |
| 08.11.2023 | Araris to develop drug candidates for Japanese pharma company | |
| 09.10.2023 | Industry veterans take on executive roles in startups | |
| 19.05.2023 | Cash and honorary awards for Swiss innovators | |
| 05.05.2023 | Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates | - |
| 05.05.2023 | Araris Biotech Receives CHF 2.5M Grant Funding | Araris Biotech AG, a Swiss company pioneering proprietary antibody-drug conjugate (ADC)-linker technology, received a CHF 2.5M non-dilutive grant funding.
Innosuisse, the Swiss innovation agency committed to promote science-based innovation... |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 18.04.2023 | Araris expands its pipeline towards solid tumor indications | |
| 14.04.2023 | Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023 | AU ZH, Switzerland, April 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will deliver two poster presentations at this year's A... |
| 12.04.2023 | Samsung Ventures invests in Araris Biotech | |
| 04.11.2022 | The C-suite floor as a final destination | |
| 05.10.2022 | Araris Biotech Closes $24M Funding Round | Araris Biotech AG, a AU ZH, Switzerland-based antibody-drug conjugate company, raised $24M in funding.
The round was co-led by 4BIO Capital, and Pureos Bioventures, with participation from Wille AG, Follicular Lymphoma Innovation, VI Partne... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | AU ZH, SWITZERLAND / October 4, 2022 / Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | /EIN News/ -- ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 mil... |
| 04.10.2022 | Araris Biotech Closes $24 Million Financing Round | ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing... |
| 04.10.2022 | Araris Biotech closes USD 24 million financing round | Araris Biotech closes USD 24 million financing round 04.10.2022 16:30, Tracy Woodley linkedIn facebook twitter instagram youtube -->
Araris Biotech, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, toda... |
| 04.10.2022 | Araris Biotech closes USD 24 million financing round | Araris Biotech is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off-the-shelf’ ... |
| 08.02.2022 | 1100 Quadratmeter für zwei Biotech-Highflyer | |
| 22.10.2020 | Araris Biotech raises CHF 15.2 million to boost the development of their antibody-drug conjugate (ADC)-linker technology | Araris Biotech raises CHF 15.2 million to boost the development of their antibody-drug conjugate (ADC)-linker technology 22.10.2020 10:53, Jonatan Masseus linkedIn facebook twitter instagram youtube -->
The Zurich based company Araris Bi... |
| 22.10.2020 | A CHF 15.2 Million seed investment brings Araris Biotech a step further | There are nine antibody-drug conjugates (ADC) approved by the FDA; however, many of them cannot be dosed high enough to elicit efficacy. This is due to systemic toxicity often caused by linker instability or heterogeneous distributions of t... |
| 22.10.2020 | 4BIO Capital invests in Araris Biotech AG’s CHF 15.2 million seed financing round | · Dmitry Kuzmin, Managing Partner, to join as Board member |
| 22.10.2020 | A CHF 15.2 Million seed investment brings Araris Biotech a step further | |
| 22.10.2020 | Araris Biotech Completes CHF 15.2 Million Seed Financing Round | Round led by Pureos Bioventures with new and existing investors, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder AdveqProceeds to support advancement of lead antibody-drug conjugates (ADCs) into preclinical and... |
| 22.10.2020 | Araris Biotech raises CHF 15.2 million to boost the development of their antibody-drug conjugate (ADC)-linker technology | Araris Biotech, a Swiss Biotech start-up focuses on the commercialization of novel antibody-drug conjugate (ADC)-linker technology. This enable fast and precise production of ADCs using their proprietary peptide linkers. The innovative appr... |
| 22.10.2020 | Araris Biotech Closes CHF15.2M Seed Financing | Araris Team
Araris Biotech AG, a Zurich, Switzerland-based company pioneering antibody-drug conjugate (ADC)-linker technology, received an additional CHF 12.7m in seed financing, bringing the total amount raised to CHF 15.2m.
The round was ... |
| 23.04.2020 | Ten Venture Leaders Life Sciences startups prepare for the Boston roadshow in November | Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion. For the next Venture leaders Life sciences one-week roadshow to Boston, ten startups selected from 60 a... |
| 23.04.2020 | Ten Venture Leaders Life Sciences startups prepare for the Boston roadshow in November | |
| 20.12.2019 | TOP 100 - Meet the 5 Youngest Startups of 2019 Ranking | TOP 100 - Meet the 5 Youngest Startups of 2019 Ranking 20.12.2019 11:15, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
The TOP 100 Swiss Startup Award ranking features young companies from a range of different sectors.... |
| 17.12.2019 | Cellestia Biotech AG Raises CHF 20M to Finance Clinical Trial of its Gene Transcription Cancer Therapy | Cellestia Biotech AG Raises CHF 20M to Finance Clinical Trial of its Gene Transcription Cancer Therapy 17.12.2019 16:42, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
The financing round was led by FC Capital, Shanghai... |
| 26.08.2019 | Araris Biotech Closes CHF2.5M Seed Financing | Araris Biotech, a Zurich, Switzerland-based developer of proprietary antibody-drug conjugates (ADCs), closed CHF2.5M seed financing round.
Backers included Redalpine, Schroder Adveq and VI Partners.
The company intends to use the funds for ... |
| 20.08.2019 | Araris Biotech Raises CHF 2.5 million to Develop own Antibody-Drug-Conjugates | What is Araris Biotech AG's mission and core innovation?
Our platform allows scientists to attach any payload to ‘off the shelf’ antibodies, without any prior antibody engineering. The resulting ADCs have well-defined drug-to-antibody ratio... |
| 20.08.2019 | Araris obtains CHF 2.5 million after only six months of existence | |
| 25.06.2019 | Support for concrete printing robots and cancer-killing drugs | |
| 22.06.2018 | Die Finalisten des Wettbewerbs >>venture>> stehen fest | |
| - | Araris Biotech | “Araris Biotech” |
